Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | TIPARP | Q7Z3E1 | 7/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 5/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2598421 | 1.00 | CHRM4 (0.42) | CHRM4ROCK2CCR2ROCK1TIPARP | |
| SCHEMBL2598593 | 0.81 | CHRM4 (0.46) | CHRM4ROCK2CCR2ROCK1TIPARP | |
| SCHEMBL2598596 | 0.81 | CHRM4 (0.46) | CHRM4ROCK2CCR2ROCK1TIPARP | |
| SCHEMBL15022677 | 0.77 | GPR119 (0.40) | TIPARP | |
| SCHEMBL15022673 | 0.77 | GPR119 (0.40) | TIPARP | |
| SCHEMBL2598532 | 0.76 | PIK3CD (0.49) | CHRM4ROCK2CCR2ROCK1 | |
| SCHEMBL2598533 | 0.76 | PIK3CD (0.49) | CHRM4ROCK2CCR2ROCK1 | |
| SCHEMBL15023109 | 0.75 | KCNJ1 (0.36) | TIPARPKCNH2 | |
| SCHEMBL2598425 | 0.70 | GPR119 (0.42) | TIPARPKCNH2 | |
| SCHEMBL15023098 | 0.70 | GPR119 (0.42) | TIPARPKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
| EP-2571864-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146335-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | CHRM4 734/4885ROCK2 3201/4885CCR2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.